EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Long‐Term Neurodevelopmental Outcome Following Three Randomized Controlled Trials of Choline in Fetal Alcohol Spectrum Disorder ( FASD )

Jeffrey R Wozniak iD, Judith K Eckerle iD, Blake A Gimbel iD, Abigail M Ernst iD, Mary E Anthony, Kent A Tuominen, Erik de Water, Alexandra L Doughty, Steven H Zeisel iD, Michael K Georgieff

Alcohol, Clinical and Experimental Research · 2026

DOI: 10.1111/acer.70394 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alcohol, Clinical and Experimental Research, 2026. Verfasst von Jeffrey R Wozniak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry & Behavioral Sciences, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Fetal Alcohol Spectrum Disorders, Choline. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health (NIH), NIAAA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fetal alcohol spectrum disorder (FASD) represents a range of neurodevelopmental outcomes from prenatal alcohol exposure for which there are few interventions. Preclinical studies have identified choline as a potential treatment for cognitive deficits in FASD. We previously conducted three randomized controlled trials (RCTs) in children under age 6 and reported on memory benefits following all three trials. Two RCTs compared a fixed 500 mg daily dose to placebo, and the third RCT tested a weight‐adjusted choline dose. Here, we report on a longitudinal follow‐up 5 years post‐study completion.

Methods

The RCTs included 2.5‐ to 5.9‐year‐old children with FASD who received choline ( n = 53) or placebo ( n = 51). Participants described here ( n = 28 choline; n = 30 placebo) were 9.1 years old on average at follow‐up. Of these, 9% had fetal alcohol syndrome (FAS), 43% partial FAS (PFAS), and 48% alcohol‐related neurodevelopmental disorder (ARND). Parents completed a diagnostic interview and behavior checklists while participants completed assessments of general cognitive ability, executive functioning, and memory.

Results

Participants who received choline in the initial RCT showed a medium effect size performance advantage (9.1% better) for non‐verbal IQ and a medium effect size advantage (11.3% better) for working memory over placebo. Age at enrollment did not explain significant variance in outcome but choline dose was significantly associated with non‐verbal IQ and working memory (higher dose contributed to better performance at follow‐up). High rates of anxiety disorders and impulse‐control disorders were observed. While there were no statistically significant differences in mental health diagnoses for choline versus placebo, there were some differences that neared significance.

Conclusions

Very few RCTs have been conducted in FASD, and interventions targeting cognitive functioning are needed. The data reported here suggest that choline supplementation has long‐lasting neurodevelopmental benefits, especially in non‐verbal IQ and working memory for individuals with FASD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fetal Alcohol Spectrum DisordersCholineHumansFemaleChild, PreschoolChildMalePregnancyFollow-Up StudiesLongitudinal StudiesNeurodevelopmentTreatment OutcomeCognitionExecutive Function

Stichwörter der Autor:innen

cholinecognitionfetal alcohol spectrum disorderslongitudinal studies

Substanzen

Choline

Autor:innen und Institutionen

  • Department of Psychiatry & Behavioral Sciences, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Pediatric Psychology & Neuropsychology, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Great Lakes Neurobehavioral Center, Eagan, Minnesota, USA.
  • University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

ORCID-Profile: Jeffrey R Wozniak, Judith K Eckerle, Blake A Gimbel, Abigail M Ernst, Steven H Zeisel

Förderung

  • National Institutes of Health (NIH)
  • NIAAA NIH HHS

Zitieren

APA

Wozniak, J. R., Eckerle, J. K., Gimbel, B. A., Ernst, A. M., Anthony, M. E., Tuominen, K. A., de Water, E., Doughty, A. L., Zeisel, S. H., & Georgieff, M. K. (2026). Long‐Term Neurodevelopmental Outcome Following Three Randomized Controlled Trials of Choline in Fetal Alcohol Spectrum Disorder ( FASD ). Alcohol, Clinical and Experimental Research. https://doi.org/10.1111/acer.70394

Vancouver

Wozniak JR, Eckerle JK, Gimbel BA, Ernst AM, Anthony ME, Tuominen KA, et al. Long‐Term Neurodevelopmental Outcome Following Three Randomized Controlled Trials of Choline in Fetal Alcohol Spectrum Disorder ( FASD ). Alcohol, Clinical and Experimental Research. 2026. doi:10.1111/acer.70394

BibTeX
@article{Wozniak2026,
  author = {Wozniak, Jeffrey R and Eckerle, Judith K and Gimbel, Blake A and Ernst, Abigail M and Anthony, Mary E and Tuominen, Kent A and de Water, Erik and Doughty, Alexandra L and Zeisel, Steven H and Georgieff, Michael K},
  title = {Long‐Term Neurodevelopmental Outcome Following Three Randomized Controlled Trials of Choline in Fetal Alcohol Spectrum Disorder ( FASD )},
  journal = {Alcohol, Clinical and Experimental Research},
  year = {2026},
  doi = {10.1111/acer.70394}
}
Kostenlos starten →